{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:09:28Z","timestamp":1763748568511,"version":"3.40.5"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Vet Comparative Oncology"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lomustine (1\u2010[2\u2010chloroethyl]3\u2010cyclohexyl\u20101\u2010nitrosurea, CCNU) is an oral alkylating agent in the nitrosourea subclass that can cause myelosuppression, with neutropenia being the main dose\u2010limiting toxicity. The aim of this study was to define the frequency of neutropenic events and to identify predisposing risk factors in tumour\u2010bearing dogs treated with CCNU. Dogs receiving CCNU for various malignancies were identified following a search of hospital databases. Variables analysed for correlation with neutropenia included signalment, body weight, tumour type, CCNU total dose, steroid use, protocol type, use of L\u2010asparaginase, previous anthracycline administration and use of the drug as first\u2010line or in the rescue setting. One\u2010hundred and fifteen cases were included; median age was 7\u2009years (range 1\u201314\u2009years) and median body weight 27.6\u00a0kg (range 3\u201374\u2009kg). The median CCNU dose was 63.5\u00a0mg\/m<jats:sup>2<\/jats:sup>(range 27.7\u201384.9\u00a0mg\/m<jats:sup>2<\/jats:sup>). Neutropenia occurred in 75 cases (65%) and was comprised of grade 1 (28%), 2 (16%), 3 (29.3%) and 4 (26.7%) events. Tumour type (histiocytic sarcoma [HS]), use of CCNU first line, dose &gt;70\u2009mg\/m<jats:sup>2<\/jats:sup>, absence of co\u2010morbidities and previous anthracycline administration, were significantly associated with an increased risk of developing neutropenia, including high\u2010grade events. There was a 1.7% reported mortality rate. When CCNU is used in dogs with HS, first\u2010line, at a starting dosage &gt;70\u2009mg\/m<jats:sup>2<\/jats:sup>, in patients with no co\u2010morbidities or with a history of previous anthracycline administration, there may be an increased risk of developing neutropenia. These data may help guide treatment decisions and minimize treatment delays or potentially life\u2010threatening complications.<\/jats:p>","DOI":"10.1111\/vco.12809","type":"journal-article","created":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T15:00:04Z","timestamp":1646578804000},"page":"577-586","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk factors associated with the onset of lomustine\u2010induced neutropenia in tumour\u2010bearing dogs"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5081-2440","authenticated-orcid":false,"given":"Elisabetta","family":"Treggiari","sequence":"first","affiliation":[{"name":"Centro Specialistico Veterinario, Oncology service Milan Lombardy Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Cossu","sequence":"additional","affiliation":[{"name":"Willows Veterinary Centre and Referral Service, Oncology service Solihull West Midlands UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Valenti","sequence":"additional","affiliation":[{"name":"Clinica Veterinaria Malpensa, Oncology service Samarate Lombardy Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3852-0127","authenticated-orcid":false,"given":"Angela","family":"Taylor","sequence":"additional","affiliation":[{"name":"Royal Veterinary College Queen Mother Hospital for Animals, Oncology service Hatfield Hertfordshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1999.tb02217.x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2006.tb00756.x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2006.tb02833.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1999.tb01452.x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.230.12.1866"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2007.tb02937.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2009.00197.x"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2011.0743.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2010.00217.x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2010.0588.x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.5326\/JAAHA-MS-6020"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.13805"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5810.2006.00088.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.239.2.209"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12091"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2009.00190.x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12329"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2010.00224.x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12378"},{"issue":"4","key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2460\/javma.1997.210.04.512","article-title":"Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987\u20101995)","volume":"210","author":"Valerius KD","year":"1997","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.5326\/0410221"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2006.tb00719.x"},{"issue":"2","key":"e_1_2_10_24_1","first-page":"175","article-title":"The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma","volume":"55","author":"Parsons\u2010Doherty M","year":"2014","journal-title":"Can Vet J"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12457"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2009.00200.x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12032"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.283"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/avj.12767"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12198"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2001.tb02311.x"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2008.00175.x"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(82)80043-1"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2012.06.010"}],"container-title":["Veterinary and Comparative Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vco.12809","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vco.12809","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vco.12809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T20:50:24Z","timestamp":1726779024000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vco.12809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/vco.12809"],"URL":"https:\/\/doi.org\/10.1111\/vco.12809","archive":["Portico"],"relation":{},"ISSN":["1476-5810","1476-5829"],"issn-type":[{"type":"print","value":"1476-5810"},{"type":"electronic","value":"1476-5829"}],"subject":[],"published":{"date-parts":[[2022,3,11]]},"assertion":[{"value":"2021-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}